Table 2.
Baseline characteristics of eligible randomized clinical trials.
| Reference | Location | Intervention | End Point measurement (months) | Total No. | Mean age (years) | Sex (M/F) | Baseline IOP (mm Hg) [mean (SD)] | Quality score (%) |
|---|---|---|---|---|---|---|---|---|
| El Sayyad et al. 2000 [12] | Saudi Arabia | DS; TE | 12 | 39 | 53 | 15/24 | 28.1 (5.4) | 60 |
| Chiselita et al. 2001 [13] | Romania | DS; TE | 18 | 17 | 60 | 9/8 | 27.5 (2.2) | 60 |
| Jonescu-Cuypers et al. 2001 [14] | Germany | VCO; TE | 6 | 20 | 63 | 11/9 | 29.7 (6.5) | 55 |
| Kozobolis et al. 2002 [15] | Greece | DS; DS-MMC | 36 | 90 | 68 | 41/49 | 26.7 (4.2) | 60 |
| Lüke et al. 2002 [16] | Germany | VCO; TE | 12 | 60 | 61 | 29/31 | 27.1 (7.1) | 60 |
| O’Brart et al. 2002 [17] | United Kingdom | VCO; TE | 19 | 50 | 65 | 32/18 | 24.1 (6.6) | 70 |
| Wang et al. 2002 [18] | China | DS-RHAI; TE | 6 | 168 | NR | NR | 32.2 (4.7) | 55 |
| Carassa et al. 2003 [19] | Italy | VCO; TE | 24 | 50 | 68 | 20/30 | 23.8 (7.0) | 75 |
| D’Eliseo et al. 2003 [20] | Italy | DS-RHAI; PDS-RHAI | 12 | 42 | 75 | 23/19 | 23.2 (2.9) | 50 |
| Kobayashi et al. 2003 [21] | Japan | VCO; TE-MMC | 12 | 25 | 63 | 11/14 | 24.9 (2.4) | 55 |
| Lüke et al. 2003 [22] | Germany | VCO; VCO-RHAI | 12 | 40 | 61 | 33/7 | 26.5 (6.1) | 55 |
| Cillino et al. 2004 [23] | Italy | DS; TE | 24 | 35 | 70 | 17/18 | 31.2 (11.7) | 60 |
| Egrilmez et al. 2004 [24] | Turkey | DS-TI; VCO; TE | 6 | 34 | 62 | 21/13 | 28.6 (11.1) | 65 |
| Neudorfer et al. 2004 [25] | Israel | DS-CI; DS-CI-MMC | 24 | 26 | 67 | 13/13 | 29.0 (4.9) | 55 |
| O’Brart et al. 2004 [26] | United Kingdom | VCO; TE | 24 | 50 | 60 | 35/15 | 26.7 (7.3) | 70 |
| Ravinet et al. 2004 [27] | Switzerland | DS-TI; DS | 24 | 22 | 76 | 7/15 | 25.8 (12.5) | 50 |
| Schwenn et al. 2004 [28] | Germany | DS-RHAI-MMC; TE-MMC | 12 | 22 | 68 | 11/11 | 25.1 (10.1) | 60 |
| Shaarawy et al. 2004 [29] | Switzerland | DS-CI; DS | 48 | 104 | 72 | 53/51 | 24.5 (6.4) | 50 |
| Yalvac et al. 2004 [30] | Turkey | VCO; TE | 36 | 50 | 60 | 36/14 | 36.9 (8.5) | 55 |
| Shaarawy et al. 2005 [31] | Switzerland | DS-CI; DS | 54 | 13 | 79 | 3/10 | 24.7 (4.5) | 55 |
| Huang et al. 2006 [32] | China | DS-MMC; TE-MMC | 48 | 105 | 59 | 64/41 | 28.4 (8.4) | 50 |
| Mansouri et al. 2006 [33] | Austria | DS-PMMAI; DS-CI | 30 | 53 | 70 | 22/31 | 21.2 (7.4) | 60 |
| Mielke et al. 2006 [34] | Nigeria | DS; DS-MMC | 24 | 39 | 59 | 29/10 | 28.1 (7.2) | 55 |
| Cillino et al. 2008 [35] | Italy | DS-MMC; TE-MMC | 48 | 40 | 70 | 20/20 | 28.8 (5.9) | 70 |
| Leszczyński et al. 2008 [36] | Poland | DS-RHAI-MMC; VDS-RHAI-MMC | 12 | 50 | 58 | 36/14 | 23.8 (3.0) | 50 |
| Russo et al. 2008 [37] | Italy | DS-RHAI-MMC; TE-MMC | 48 | 93 | 67 | 47/46 | 25.7 (2.9) | 55 |
| Gilmour et al. 2009 [38] | United Kingdom | VCO; TE | 60 | 43 | 64 | 29/14 | 25.2 (4.0) | 55 |
| Mansouri et al. 2009 [39] | Switzerland | DS-MMC; DS-D-MMC | 24 | 25 | 73 | 10/15 | 21.1 (8.0) | 60 |
| Mansouri et al. 2009 [40] | Switzerland | DS-CI; VDS-CI | 24 | 50 | 67 | 26/24 | 21.4 (6.4) | 75 |
M – male; F – female; IOP – intraocular pressure; SD – standard deviation; DS – deep sclerectomy; VCO – viscocanalostomy; TE – trabeculectomy; CI – collagen implant; RHAI – reticulated hyaluronic acid implant; TI – T-flux® implant; PMMAI – polymethylmethacrylate implant; MMC – mitomycin C; D-MMC – mitomycin C applied under the deep sclera flap; PDS – combined deep sclerectomy and phacoemulsification; VDS – very deep sclerectomy; NR – not reported.